kind of extra-extra-nodal nasal natural killer cell lymphoma (ENKL) has been recognized with a worse prognosis than other types of nose with the worst response to treatment. Work is currently introducing ENKL case with GI involvement without manifestation nose. We report a male farmers 56 years with fever, nonproductive cough, dyspnea, anorexia, vomiting and chill besides malaise and cachexia duration of three months referred to hospital with acute abdominal pain and was diagnosed as peritonitis due to perforated terminal ileum ulcer before having surgery as a case of acute abdomen. Study pathological biopsy relevant show “ulceration and necrosis with exudation fibrinoleukocytic solid and granulation tissue formation. CT scans determined the mass of bilateral as blurring the more likely metastasis.
Overview of the pathological specimens previously raised Natural Killer / T-cell lymphoma (NKTL), reason our focus on the sinus patient and the area of the nose and nasopharynx. there are no findings in the examination and endoscopic sinus. Pathology also found cell lymphoma of high grade non-Hodgkin T malignant specimens obtained from debridement of ulcers in the terminal ileum. it also shows that the majority of tumor cells were positive for CD3, CD56, CD8, and LCA but negative for CD19, CD20 and reaction AE1 / AE3, positive for CD30 demonstrated by several cells. CD56, CD3 and CD8 expressed by neoplastic cells and CD30 positive in some cells, the activity of proliferative (Ki67 index) is high (60-70%). this is the main basis for diagnosis n Odal extra-extra-cell lymphoma nasal NK / T In conclusion, intestinal changes in middle age, especially in men with non-specific clinical manifestations are strongly advised to study the pathological and genetic types of T cells such as cells are CD30 positive T are usually involved in ENKTL.
Oct4 Set Transition Cancer Stem-Like Cells to Tumor Endothelial-Like Human Liver Cancer Cells
Octamer-binding transcription factor 4 (Oct4) was recently involved as a regulator proangiogenic at some ips cells (iPSCs), but its role in cancer stem-like cells (CSC) remains unclear. We report here that Oct4 participate in vasculogenesis CSC tumor in the liver (LCSCs). We identified that LCSCs potential trans-differentiation of endothelial under induction of endothelial, present specific endothelial markers and their function in vitro and in vivo participate in neovasculogenesis.
Knockdown of Oct4A by short hairpin RNA (shRNA) in LCSCs repressing trans-differentiation of endothelial potential, but induces endothelial differentiation-restricted offspring, the latter regulated positively by Oct4B1. Furthermore, Oct4 regulate vasculogenesis in LCSCs possibly through Akt-NF-kB-p65 signaling pathway. This work revealed Oct4, which is an important regulator, plays an important role in tumor endothelial-like cells transition from LCSCs through Oct4A and Oct4B1 by different ways. Simultaneous inhibition of both isoforms of Oct4 is then expected regression of neovascularization assistance derived from CSC. Our findings may provide insight into the possible new mechanism for tumor vasculogenesis primary liver cancer.
Clear cell renal cell carcinoma (ccRCC) is a common genitourinary cancer associated with the development of abnormal tumor angiogenesis.
Although several anti-angiogenic therapies have been developed, in response to the individual treatments varies greatly between patients. Thus, the use of single-patient clinical trial has been suggested as an alternative to standard trialsWe use of microfluidic devices for generating patient-specific blood vessels Organotypic main model using normal (NEnC) and tumor-associated CD31 + cells are selected basis (TEnC). Our model is able to recapitulate the differences angiogenic sprouting and vessel permeability that characterize normal and tumor-associated vessels.
Zingiberene targeting miR-16 / cyclin-B1 axis to regulate the growth, migration and invasion of human liver cancer cells
Objective: The liver cancer or hepatocellular carcinoma (HCC) is regarded as one of the most frequent malignancy with a fairly high morbidity and mortality worldwide. MicroRNAs (Mirs) is regarded as an important regulator of liver cancer formation and development. However, the biochemical mechanism of the full their role is still very poorly understood. The main objective of the current research work is to examine the role of miR-16 / cyclin-B1-axis in the regulation of liver cancer and how this pathway together with the migration and invasion of liver cancer molecular targeted by zingiberene.
Methods: Quantitative reverse transcriptase polymerase chain reaction was used to evaluate miR-16 expression in liver cancer cell lines. Western blotting was performed to evaluate the expression of miR-16 target genes. The effects on cell migration and invasion were evaluated in vitro wound healing assay and Matrigel transwell assay, respectively. Effects of zingiberene in HCC cell viability was evaluated by MTT assay.
Results: zingiberene treatment causes downregulation of miR-16 in human hepatocellular carcinoma HepG2 cells, accompanied by a cycle arrest induced G0 / G1 cell targeting cyclin B1 as a direct target. This effect is also accompanied by inhibition of cell migration and invasion, suggesting that miR-16 may have an important role as a suppressor of liver cancer after treatment zingiberene. Luciferase reporter assay confirms that the miR-16, which is one of HCC downregulated Mirs, targeted direct Cyclin B1 in HCC cells.
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380570-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380570-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380570-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380571-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380571-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380571-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380571-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380571-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380572-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380572-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380572-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380572-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380572-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380939-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380939-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380939-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380939-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380939-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380940-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380940-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380940-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380940-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380940-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380941-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380941-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380941-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380941-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker) |
|||
| MBS4380941-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380792-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380792-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380792-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380792-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380792-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380793-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380793-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380793-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380793-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380793-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380794-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380794-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380794-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380794-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380794-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380795-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380795-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380795-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380795-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380795-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380796-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380796-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380796-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380796-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker) |
|||
| MBS4380796-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381327-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381327-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381327-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381327-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381327-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381328-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381328-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381328-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381328-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381328-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381329-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381329-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381329-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381329-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Uroplakin 1B (Urothelial Differentiation Marker) |
|||
| MBS4381329-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), 1mg/mL |
|||
| BNUM2441-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), 1mg/mL |
|||
| BNUM2442-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), 1mg/mL |
|||
| BNUM2444-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), 1mg/mL |
|||
| BNUM2445-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), 1mg/mL |
|||
| BNUM2446-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), 1mg/mL |
|||
| BNUM2688-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), 0.2mg/mL |
|||
| BNUB2441-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), 0.2mg/mL |
|||
| BNUB2441-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), 0.2mg/mL |
|||
| BNUB2442-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), 0.2mg/mL |
|||
| BNUB2442-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), 0.2mg/mL |
|||
| BNUB2444-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), 0.2mg/mL |
|||
| BNUB2444-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), 0.2mg/mL |
|||
| BNUB2445-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), 0.2mg/mL |
|||
| BNUB2445-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), 0.2mg/mL |
|||
| BNUB2446-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), 0.2mg/mL |
|||
| BNUB2446-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), 0.2mg/mL |
|||
| BNUB2688-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), 0.2mg/mL |
|||
| BNUB2688-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380586-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380586-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380586-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380586-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380586-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380978-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380978-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380978-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380978-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
Heregulin-1/Neuregulin-1 (Breast and Urothelial Marker) |
|||
| MBS4380978-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2921), 1mg/mL |
|||
| BNUM2921-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2922), 1mg/mL |
|||
| BNUM2922-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2923), 1mg/mL |
|||
| BNUM2923-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2924), 1mg/mL |
|||
| BNUM2924-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2925), 1mg/mL |
|||
| BNUM2925-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3081), 1mg/mL |
|||
| BNUM3081-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3102), 1mg/mL |
|||
| BNUM3102-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3273), 1mg/mL |
|||
| BNUM3273-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2921), 0.2mg/mL |
|||
| BNUB2921-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2921), 0.2mg/mL |
|||
| BNUB2921-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2922), 0.2mg/mL |
|||
| BNUB2922-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2922), 0.2mg/mL |
|||
| BNUB2922-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2923), 0.2mg/mL |
|||
| BNUB2923-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2923), 0.2mg/mL |
|||
| BNUB2923-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2924), 0.2mg/mL |
|||
| BNUB2924-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2924), 0.2mg/mL |
|||
| BNUB2924-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2925), 0.2mg/mL |
|||
| BNUB2925-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1A (Urothelial Differentiation Marker)(UPK1A/2925), 0.2mg/mL |
|||
| BNUB2925-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3081), 0.2mg/mL |
|||
| BNUB3081-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3081), 0.2mg/mL |
|||
| BNUB3081-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3102), 0.2mg/mL |
|||
| BNUB3102-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3102), 0.2mg/mL |
|||
| BNUB3102-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3273), 0.2mg/mL |
|||
| BNUB3273-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Uroplakin 1B (Urothelial Differentiation Marker)(UPK1B/3273), 0.2mg/mL |
|||
| BNUB3273-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Upper tract urothelial carcinoma (UTUC) with normal tissue array |
|||
| UR1002 | TissueArray | each | EUR 306 |
|
Description: Upper tract urothelial carcinoma (UTUC) with normal tissue array, including TNM and clinical stage (reference AJCC 8th version), 100 cases/100 cores |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF568 conjugate, 0.1mg/mL |
|||
| BNC682441-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF568 conjugate, 0.1mg/mL |
|||
| BNC682441-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF568 conjugate, 0.1mg/mL |
|||
| BNC682442-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF568 conjugate, 0.1mg/mL |
|||
| BNC682442-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), CF568 conjugate, 0.1mg/mL |
|||
| BNC682444-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), CF568 conjugate, 0.1mg/mL |
|||
| BNC682444-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), CF568 conjugate, 0.1mg/mL |
|||
| BNC682445-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), CF568 conjugate, 0.1mg/mL |
|||
| BNC682445-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), CF568 conjugate, 0.1mg/mL |
|||
| BNC682446-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), CF568 conjugate, 0.1mg/mL |
|||
| BNC682446-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), CF568 conjugate, 0.1mg/mL |
|||
| BNC682688-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), CF568 conjugate, 0.1mg/mL |
|||
| BNC682688-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF594 conjugate, 0.1mg/mL |
|||
| BNC942441-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF594 conjugate, 0.1mg/mL |
|||
| BNC942441-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF594 conjugate, 0.1mg/mL |
|||
| BNC942442-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF594 conjugate, 0.1mg/mL |
|||
| BNC942442-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), CF594 conjugate, 0.1mg/mL |
|||
| BNC942444-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), CF594 conjugate, 0.1mg/mL |
|||
| BNC942444-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), CF594 conjugate, 0.1mg/mL |
|||
| BNC942445-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2445), CF594 conjugate, 0.1mg/mL |
|||
| BNC942445-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), CF594 conjugate, 0.1mg/mL |
|||
| BNC942446-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2446), CF594 conjugate, 0.1mg/mL |
|||
| BNC942446-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), CF594 conjugate, 0.1mg/mL |
|||
| BNC942688-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2688), CF594 conjugate, 0.1mg/mL |
|||
| BNC942688-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF647 conjugate, 0.1mg/mL |
|||
| BNC472441-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2441), CF647 conjugate, 0.1mg/mL |
|||
| BNC472441-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF647 conjugate, 0.1mg/mL |
|||
| BNC472442-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2442), CF647 conjugate, 0.1mg/mL |
|||
| BNC472442-500 | Biotium | 1uL | EUR 532 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
GATA-3 (Breast and Urothelial Marker)(GATA3/2444), CF647 conjugate, 0.1mg/mL |
|||
| BNC472444-100 | Biotium | 1uL | EUR 192 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
High-throughput microfluidic continuous flow electroporation of mRNA into human T cell primary for applications in manufacturing cellular therapy
Implementation of gene editing technology such as CRISPR / Cas9 in the manufacture of new cell-based therapies have the potential to enable highly targeted, stable and persistent modification of the genome without the use of viral vectors. Electroporation has emerged as the preferred method to deliver the gene-editing machine to the target cells, but the main challenge remaining is that most commercial electroporation machine built for the research and development process is not for large-scale, automated manufacturing cell therapy.
Here we present electrotransfection continuous-flow microfluidic device designed for precise, consistent, and high-throughput genetic modification of target cells in cell therapy manufacturing applications. We optimized our device for the delivery of mRNA in primary human T cells and show up to 95% transfection efficiency with minimal impact on cell viability and expansion potential.